AB Science SA AB

PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 14.2 MILLION PRIVATE PLACEMENT, PRIMARILY SUSBCRIBED BY LONG TERM INVESTOR AB SCIENCE CASH POSITION IS AROUND EUR 23 MILLION AFTER THIS PRIVATE PLACEMENT, THEREBY ALLOWING THE COMPANY TO CARRY-OUT WITHOUT ANY ADDITIONAL NEAR-TERM FINANCING THE FIRST STEPS OF ITS STRATEGIC PLAN TO BE FINALIZED AND ANNOUNCED IN SEPTEMBER Paris, August 10, 2026, 8am AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) ann

The Alzheimer's disease treatment landscape is experiencing a major transformation with the introduction of disease-modifying therapies that target fundamental disease mechanisms, particularly amyloid-β pathology. Among these, LEQEMBI (lecanemab) has become a leading biologic for patients with early-stage Alzheimer's disease, demonstrating its ability to slow cognitive and functional deterioration in biomarker-confirmed individuals. Regulatory approvals across key global markets have strengthene

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM, SUSPENDING SOME NON-PRIORITY CLINICAL TRIALS TO FOCUS ON TWO CLINICAL PROGRAMS Paris, July 10, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today provides an update on its clinical development program and announces the discontinuation of certain non-priority clinical studies in order to focus on two clinical programs, the AB8939 program for acute myeloid leukemia and the masitinib program for amyotrophic lateral s